Globus Medical, Inc., a medical device company, focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The company offers products that address a variety of musculoskeletal pathologies, anatomies, and surgical approaches. Its spine product portfolio includes a range of implant and surgical approach options that could be used to treat degenerative, deformity, tumor, and trauma conditions affecting the spine from the occiput to the sacrum. The company also offers imaging, navigation, and robotic assisted surgery technology solutions, as well as motion preservation technologies, such as dynamic stabilization, total disc replacement and interspinous distraction devices, and interventional pain management solutions to treat vertebral compression fractures. In addition, it provides regenerative biologic products, such as allografts and synthetic alternatives that are adjunctive treatments used in combination with stabilizing implant hardware. Further, the company offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems. Additionally, it distributes human cell, tissue, and cellular and tissue based products. The company sells its implants and related disposables primarily to hospitals through direct sales representatives and independent distributors in the United States and internationally. Globus Medical, Inc. was founded in 2003 and is headquartered in Audubon, Pennsylvania.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Phone610-930-1800
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$712.97 million
Profitability
Miscellaneous
Employees1,800
Next Earnings Date8/7/2019 (Estimated)
OptionableOptionable
Globus Medical (NYSE:GMED) Frequently Asked Questions
What is Globus Medical's stock symbol?
Globus Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "GMED."
How were Globus Medical's earnings last quarter?
Globus Medical Inc (NYSE:GMED) announced its quarterly earnings results on Thursday, May, 2nd. The medical device company reported $0.36 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.41 by $0.05. The medical device company earned $182.90 million during the quarter, compared to analysts' expectations of $186.59 million. Globus Medical had a net margin of 20.81% and a return on equity of 14.09%. Globus Medical's revenue for the quarter was up 4.9% compared to the same quarter last year. During the same quarter last year, the firm posted $0.41 earnings per share. View Globus Medical's Earnings History.
When is Globus Medical's next earnings date?
What guidance has Globus Medical issued on next quarter's earnings?
Globus Medical updated its FY 2019 earnings guidance on Thursday, May, 2nd. The company provided earnings per share guidance of $1.72-1.72 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.71. The company issued revenue guidance of $770-770 million, compared to the consensus revenue estimate of $770.74 million.
What price target have analysts set for GMED?
9 brokerages have issued 12-month target prices for Globus Medical's shares. Their forecasts range from $49.00 to $65.00. On average, they anticipate Globus Medical's stock price to reach $56.8889 in the next year. This suggests a possible upside of 36.5% from the stock's current price. View Analyst Price Targets for Globus Medical.
What is the consensus analysts' recommendation for Globus Medical?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Globus Medical in the last year. There are currently 1 sell rating, 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Globus Medical.
What are Wall Street analysts saying about Globus Medical stock?
Here are some recent quotes from research analysts about Globus Medical stock:
- 1. According to Zacks Investment Research, "Globus Medical ended the fourth quarter 2019 on a positive note with better-than-expected earnings and revenue performances. The company witnessed strength in the United States and the international regions as well as in the Musculoskeletal solutions and Enabling Technologies segments. Supported by its focus on the priority areas like efforts in innovation and research and development, the company has again delivered strong top-line numbers for its Spine arm. Implant pull-through from ExcelsiusGPS placements and back-to-back record sales force recruiting years were the primary growth drivers. However, escalating costs and expenses weighed on the company’s margins. This apart, the pricing scenario is persistently tough for Globus Medical. Overall, the stock has underperformed its industry in the past three months." (4/24/2019)
- 2. Cantor Fitzgerald analysts commented, "We reiterate our Overweight rating on GMED with a 12-month price target of $60. We think GMED has several top-line growth drivers, including a US core market rebound, early success of emerging technologies and traction of the acquired ATEC international platform. GMED’s best-in-class profitability allows the company to invest organically or inorganically to drive top-line growth and to react to the evolving trends of the spine market. These should bring the company back to the beat-and-raise philosophy of a couple of years ago and help to push the valuation higher." (3/1/2019)
Has Globus Medical been receiving favorable news coverage?
Media stories about GMED stock have been trending somewhat negative recently, according to InfoTrie. The research firm ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Globus Medical earned a media sentiment score of -1.6 on InfoTrie's scale. They also gave media coverage about the medical device company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the next few days.
Who are some of Globus Medical's key competitors?
Some companies that are related to Globus Medical include ResMed (RMD), Teleflex (TFX), ABIOMED (ABMD), DexCom (DXCM), Hill-Rom (HRC), Insulet (PODD), Haemonetics (HAE), Penumbra (PEN), Novocure (NVCR), ICU Medical (ICUI), Integra Lifesciences (IART), Tandem Diabetes Care (TNDM), NuVasive (NUVA), Merit Medical Systems (MMSI) and Cantel Medical (CMD).
What other stocks do shareholders of Globus Medical own?
Who are Globus Medical's key executives?
Globus Medical's management team includes the folowing people:
- Mr. David C. Paul, Co-Founder & Exec. Chairman (Age 52)
- Mr. David M. Demski, CEO & Director (Age 61)
- Mr. Anthony L. Williams, Pres & Corp. Sec. (Age 48)
- Mr. David D. Davidar, Co-Founder & Director (Age 53)
- Mr. Daniel T. Scavilla, CFO, Exec. VP & Chief Commercial Officer (Age 54)
Who are Globus Medical's major shareholders?
Globus Medical's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (9.67%), Wellington Management Group LLP (5.17%), Janus Henderson Group PLC (3.42%), AQR Capital Management LLC (2.24%), Investec Asset Management LTD (1.40%) and Renaissance Technologies LLC (1.37%). Company insiders that own Globus Medical stock include A Brett Murphy, Anthony L Williams, Daniel T Scavilla, David C Paul, David D Davidar, David M Demski, Eric Schwartz, James R Tobin, Kelly Huller and Steven Payne. View Institutional Ownership Trends for Globus Medical.
Which institutional investors are selling Globus Medical stock?
GMED stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Morgan Stanley, Marshall Wace LLP, Victory Capital Management Inc., AQR Capital Management LLC, JPMorgan Chase & Co., Investec Asset Management LTD and Oak Ridge Investments LLC. Company insiders that have sold Globus Medical company stock in the last year include Anthony L Williams, David C Paul, Eric Schwartz, James R Tobin, Kelly Huller and Steven Payne. View Insider Buying and Selling for Globus Medical.
Which institutional investors are buying Globus Medical stock?
GMED stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Sio Capital Management LLC, Fort Washington Investment Advisors Inc. OH, Monarch Partners Asset Management LLC, Renaissance Technologies LLC, Global Alpha Capital Management Ltd., Van Berkom & Associates Inc. and BlueMountain Capital Management LLC. View Insider Buying and Selling for Globus Medical.
How do I buy shares of Globus Medical?
Shares of GMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Globus Medical's stock price today?
One share of GMED stock can currently be purchased for approximately $41.67.
How big of a company is Globus Medical?
Globus Medical has a market capitalization of $4.12 billion and generates $712.97 million in revenue each year. The medical device company earns $156.47 million in net income (profit) each year or $1.67 on an earnings per share basis. Globus Medical employs 1,800 workers across the globe.
What is Globus Medical's official website?
How can I contact Globus Medical?
Globus Medical's mailing address is 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA, 19403. The medical device company can be reached via phone at 610-930-1800 or via email at [email protected]
MarketBeat Community Rating for Globus Medical (NYSE GMED)
MarketBeat's community ratings are surveys of what our community members think about Globus Medical and other stocks. Vote "Outperform" if you believe GMED will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GMED will underperform the S&P 500 over the long term. You may vote once every thirty days.
